Engineered oncolytic virus armed with anti-PCSK9 scFv boosts long-term CD8+ T cell immunity via rewiring MHC-I antigen presentation
T cell memory, and enhances anti-PD-1 therapy efficacy. Our results identify the role of PCSK9 in the immunosuppressive feedback following viral infection and propose a strategy for engineered oncolytic virotherapy.
Authors
- Xin Wen Guo (ORCID: https://orcid.org/0000-0003-4995-8378)
- Yuhan Zhang (ORCID: https://orcid.org/0009-0004-3328-2400)
- Jianlong Zhou (ORCID: https://orcid.org/0000-0003-2117-1100)
- Zejian Lyu
- Xiao Xiao (ORCID: https://orcid.org/0000-0001-8389-1467)
- Huolun Feng (ORCID: https://orcid.org/0009-0004-4315-3039)
- Jiabin Zheng
- W.H. Hu
- Zuda Huang
- Deqing Wu
- Yong Li
- Fan Xing
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Longgang Central Hospital (CN)
- Southern Medical University Shenzhen Hospital (CN)
- Guangdong Academy of Medical Sciences (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Cell Reports Medicine
- Published
- 2026-03-31
- DOI
- https://doi.org/10.1016/j.xcrm.2026.102724
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Chinese Pharmaceutical Association
- Southern Medical University
- Basic and Applied Basic Research Foundation of Guangdong Province